Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KABUKI: Edoxaban vs warfarin in chronic thromboembolic pulmonary hypertension
jRCT2071200098Phase 3Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of edoxaban in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Japan Agency for Medical Research and Development. Started Apr 2021; status: completed.
02
Drugs
edoxaban
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on jRCT2071200098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200098.